SEC Form 4 · accession 0000891293-16-000163
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Bianco
Officer — President and CEO · Director
Period of report
May 18, 2016
Accepted (ET)
May 20, 2016 · 4:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Opyion (Right to Buy)F1 | $0.4475 | May 18, 2016 | A | 600,000 | A | — | May 18, 2026 | Common Stock | 600,000 | 600,000 | D |
Explanation of responses
- F1The option vests 12.5% beginning on July 7, 2016 and vests an additional 12.5% every 6 months thereafter, with the final vesting on January 7, 2020, in each case subject to the reporting person's continued employment or service with the issuer through the applicable vesting date. The option can only be exercised if CTI's stock is trading at or above $1.20.